Literature DB >> 26504495

Semiparametric Contrasts of Cumulative Pre-Treatment Mortality in the Presence of Dependent Censoring.

Qi Gong1, Douglas E Schaubel2.   

Abstract

In clinical settings, the necessity of treatment is often measured in terms of the patient's prognosis in the absence of treatment. Along these lines, it is often of interest to compare subgroups of patients (e.g., based on underlying diagnosis) with respect to pre-treatment survival. Such comparisons may be complicated by at least two important issues. First, mortality contrasts by subgroup may differ over follow-up time, as opposed to being constant, and may follow a form that is difficult to model parametrically. Moreover, in settings where the proportional hazards assumption fails, investigators tend to be more interested in cumulative (as opposed to instantaneous) effects on mortality. Second, pre-treatment death is censored by the receipt of treatment and in settings where treatment assignment depends on time-dependent factors that also affect mortality, such censoring is likely to be informative. We propose semiparametric methods for contrasting subgroup-specific cumulative mortality in the presence of dependent censoring. The proposed estimators are based on the cumulative hazard function, with pre-treatment mortality assumed to follow a stratified Cox model. No functional form is assumed for the nature of the non-proportionality. Asymptotic properties of the proposed estimators are derived, and simulation studies show that the proposed methods are applicable to practical sample sizes. The methods are then applied to contrast pre-transplant mortality for acute versus chronic End-Stage Liver Disease patients.

Entities:  

Keywords:  Cumulative hazard; Informative censoring; Inverse weighting; Proportional hazards regression; Stratification; Survival analysis

Year:  2014        PMID: 26504495      PMCID: PMC4616256          DOI: 10.1007/s12561-014-9115-3

Source DB:  PubMed          Journal:  Stat Biosci        ISSN: 1867-1764


  12 in total

1.  Causal inference on the difference of the restricted mean lifetime between two groups.

Authors:  P Y Chen; A A Tsiatis
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

Authors:  J M Robins; D M Finkelstein
Journal:  Biometrics       Date:  2000-09       Impact factor: 2.571

3.  Marginal structural models and causal inference in epidemiology.

Authors:  J M Robins; M A Hernán; B Brumback
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

4.  Empirical likelihood for cumulative hazard ratio estimation with covariate adjustment.

Authors:  Bin Dong; David E Matthews
Journal:  Biometrics       Date:  2011-11-07       Impact factor: 2.571

5.  Estimating differences in restricted mean lifetime using observational data subject to dependent censoring.

Authors:  Min Zhang; Douglas E Schaubel
Journal:  Biometrics       Date:  2010-10-29       Impact factor: 2.571

6.  Estimating cumulative treatment effects in the presence of nonproportional hazards.

Authors:  Guanghui Wei; Douglas E Schaubel
Journal:  Biometrics       Date:  2007-12-05       Impact factor: 2.571

7.  Double inverse-weighted estimation of cumulative treatment effects under nonproportional hazards and dependent censoring.

Authors:  Douglas E Schaubel; Guanghui Wei
Journal:  Biometrics       Date:  2011-03       Impact factor: 2.571

8.  Estimation of treatment effect under non-proportional hazards and conditionally independent censoring.

Authors:  Adam P Boyd; John M Kittelson; Daniel L Gillen
Journal:  Stat Med       Date:  2012-07-04       Impact factor: 2.373

9.  Cumulative Hazard Ratio Estimation for Treatment Regimes in Sequentially Randomized Clinical Trials.

Authors:  Xinyu Tang; Abdus S Wahed
Journal:  Stat Biosci       Date:  2015-05

10.  End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates.

Authors:  Pratima Sharma; Douglas E Schaubel; Qi Gong; Mary Guidinger; Robert M Merion
Journal:  Hepatology       Date:  2011-11-15       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.